CLAIMS

1. Use of a pentosan polysulfate or an acceptable salt thereof, in the manufacture of a medicament for the treatment of aseptic post-operative joint pain in a mammal, wherein the aseptic post-operative joint pain is intra-articular pain that results from a joint arthroplasty.

2. The use according to claim 1, wherein the aseptic post-operative joint pain is in at least one articulating joint selected from the group consisting of: an ankle, an elbow, a finger, a hip, a knee, a shoulder, and a wrist.

3. The use according to claim 2, wherein the at least one articulating joint is a knee.

4. The use according to any one of claims 1 to 3, wherein the joint arthroplasty is a partial joint arthroplasty selected from the group consisting of: a partial ankle arthroplasty, a partial elbow arthroplasty, a partial finger arthroplasty, a partial hip arthroplasty, a partial knee arthroplasty, a partial shoulder arthroplasty, and a partial wrist arthroplasty.

5. The use according to any one of claims 1 to 3, wherein the joint arthroplasty is a total joint arthroplasty selected from the group consisting of: a total ankle arthroplasty, a total elbow arthroplasty, a total finger arthroplasty, a total hip arthroplasty, a total knee arthroplasty, a total shoulder arthroplasty, and a total wrist arthroplasty.

6. The use according to any one of claims 1 to 5, wherein the aseptic post-operative joint pain is selected from the group consisting of: acute pain; chronic pain; general pain and persistent pain.

7. The use according to claim 6, wherein the persistent pain is intra-articular persistent pain caused by a condition selected from the group consisting of: aseptic prosthetic loosening, prosthetic wear, instability, recurrent hemarthrosis, patellar maltracking and stiffness.

8. The use according to any one of the preceding claims, wherein the mammal is suffering from an additional arthritic condition further to the post-operative joint pain, wherein the additional arthritic condition is selected from the group consisting of: rheumatic arthritis, osteoarthritis and degenerative osteoarthritis.

9. The use according to claim 8, wherein the additional arthritic condition is in a second joint different from the joint affected by the post-operative pain and the pain in the second joint is reduced.

10. The use according to claim 9, wherein the second joint is one knee joint and the joint affected by the post-operative pain is another knee joint.

11. The use according to any one of the preceding claims, wherein the pentosan polysulfate (PPS) is selected from the group consisting of: the sodium salt of pentosan polysulfate (NaPPS), the magnesium salt of pentosan polysulfate (MgPPS), the calcium salt of pentosan polysulfate (CaPPS), and the zinc salt of pentosan polysulfate (ZnPPS).

12. The use according to claim 11, wherein the pentosan polysulfate (PPS) is sodium pentosan polysulfate (NaPPS).

13. The use according to any one of the preceding claims, wherein treatment is by administering the polysulfated polysaccharide or the acceptable salt thereof to the mammal in an effective amount of about 0.5 to about 2 mg/kg; about 0.5 to about 1 mg/kg; about 1.0 to about 1.5 mg/kg or about 1.5 to about 2.0 mg/kg of the mammal per dose or wherein the effective amount is a fixed dose in the range of about 25 mg to about 4000 mg.

14. The use according to claim 13, wherein the effective amount is about 0.5 mg/kg, about 1.0 mg/kg or about 2.0 mg/kg of the mammal per dose.

15. The use according to claim 13, wherein the fixed dose is about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 2000 mg, about 3000 mg or about 4000 mg.

16. The use according to any one of the preceding claims, wherein the treatment is: by administering a subcutaneous (SC) injection, an intramuscular (IM) injection, intravenous (IV) injection, intra-articular (IA) injection or a peri-articular injection; by topical administration; via suppositories or by oral administration.

17. The use according to claim 16, wherein the subcutaneous (SC) injection is a slow SC injection.

18. The use according to claim 16 or claim 17, wherein administration to a human patient is by dosing in a treatment regimen once daily, twice weekly or thrice weekly.

19. The use according to any one of the preceding claims, wherein pain in a human patient is reduced as determined by using the numerical rating scale (NRS).